A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) - COAST

Start Date30 Oct 2021

Sponsor / Collaborator

Opthea Ltd.

[+1]

CTRI/2021/10/037451 / RecruitingPhase 3

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) - ShORe

Start Date30 Oct 2021

Sponsor / Collaborator

Opthea Ltd.

[+1]

NCT04757610 / Active, not recruitingPhase 3

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Start Date12 Mar 2021

Sponsor / Collaborator

Opthea Ltd.

100 Clinical Results associated with Sozinibercept

100 Translational Medicine associated with Sozinibercept

100 Patents (Medical) associated with Sozinibercept

Literatures (Medical) associated with Sozinibercept

12 Apr 2024·Expert Opinion on Pharmacotherapy

Perspectives on the currently available pharmacotherapy for wet macular degeneration

Review

Author: Ting, Magdalene Yin Lin ; Kumar, Aneeta ; Ferro Desideri, Lorenzo ; Anguita, Rodrigo

INTRODUCTIONWet age-related macular degeneration (w-AMD) is a leading cause of visual impairment globally, with its prevalence expected to rise alongside increasing life expectancy. The current standard treatment involves frequent intravitreal injections of anti-VEGF agents, which although revolutionary, pose significant burdens on both patients and healthcare services.AREAS COVEREDThis review explores current and emerging pharmaceutical treatments for w-AMD, focusing on their pharmacokinetics, pharmacodynamics, efficacy, and safety. Promising developments include extending treatment intervals with newer anti-VEGF agents like brolucizumab and faricimab, biosimilars offering cost-effective options, and exploring innovative drug delivery methods such as subretinal gene therapy. Combination therapies, gene therapies, and novel agents like KSI-301 and OPT-302 show potential for improving treatment outcomes and reducing treatment burden.EXPERT OPINIONWhile current treatments for w-AMD have significantly advanced with the advent of anti-VEGF therapies, their limitations in terms of treatment burden and incomplete responses have spurred research into diverse alternative approaches. These innovative strategies offer hope for improving patient outcomes and reducing healthcare burdens, suggesting a promising future for w-AMD management.

01 Nov 2023·Cellular Signalling

SAR131675 exhibits anticancer activity on human ovarian cancer cells through inhibition of VEGFR-3/ERK1/2/AKT signaling pathway

Article

Author: Panjehpour, Mojtaba ; Babaei, Zeinab ; Parsian, Hadi ; Aghaei, Mahmoud

Vascular endothelial growth factor receptor-3 (VEGFR-3) is known to participate in tumorigenesis and lymphangiogenesis, and as such, has the potential to serve as a molecular target for cancer therapy. SAR131675 is a highly selective VEGFR-3 antagonist that has an inhibitive effect on lymphatic cell growth. However, the anticancer effects and underlying mechanisms of SAR131675 in ovarian cancer remain poorly understood. In this study, we investigated the pathological role of VEGFR-3, and the effects of SAR131675 on proliferation, cell cycle, migration, and apoptosis in ovarian cancer cells. Our results showed that the mRNA and protein of VEGFR-3 were expressed in OVCAR3 and SKOV3 ovarian cancer cells, and this receptor was activated following stimulation with 50 ng/ml VEGF-C Cys156Ser (VEGF-CS), a selective ligand for VEGFR-3. Enhancing VEGFR-3 phosphorylation by treatment of ovarian cancer cells with VEGF-CS resulted in increased levels of phosphorylated extracellular signal-regulated kinases 1/2 (ERK1/2) and AKT. Moreover, our data demonstrated that SAR131675 inhibited VEGF-CS-mediated proliferation, colony formation, and migration of cancer cells in a dose-dependent manner. In addition, inhibition of VEGFR-3 activation with SAR131675 significantly increased cell cycle arrest and promoted apoptosis in both OVCAR3 and SKOV3 cells. Mechanistically, SAR131675 effectively suppressed the VEGF-CS-induced phosphorylation of VEGFR-3 and its downstream effectors including activated ERK1/2 and AKT in ovarian cancer cells. Our results reveal an anticancer activity of SAR131675 on the growth and migration of ovarian cancer cells, which may be through inhibiting VEGFR-3/ERK1/2/AKT pathway. SAR131675 may serve as an effective targeted drug for ovarian cancer.

01 Jun 2023·Ophthalmology

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

Article

Author: Souied, Eric ; Wells, John ; Chao, Daniel ; Membrey, Luke ; Kousal, Bohdan ; Dugel, Pravin U. ; Walker, Joseph ; Gupta, Sunil ; Berger, Brian ; Chowers, Itay ; Raczynska, Krystyna ; Oleksy, Piotr ; Wong, Robert ; Tadayoni, Ramin ; Liyanage, Sidath ; Mrukwa-Kominek, Ewa ; Kruger, Erik ; Price, Clare F. ; Hanhart, Joel ; Alfaro, Daniel ; Pearlman, Joel ; Wagner, Alan ; Barak, Yoreh ; Gerometta, Michael ; Layana, Alfredo Garcia ; Hampton, George ; Veith, Michal ; Williams, Jonathan ; Gilmour, David ; Slakter, Jason ; Eaton, Alexander ; Batille, Ivan ; Feiner, Leonard ; Rose, Steven ; Vogt, Gabor ; Netzer, Oren Tomkins ; Ozolina, Signe ; Fein, Jordana ; Morori-Katz, Haya ; Araiz, Javier ; Dugel, Pravin ; Boyer, David S. ; Boixadera, Anna ; Rosenblatt, Irit ; Gaucher, David ; Gomez-Ulla, Francisco ; Antoszyk, Andrew ; Prensky, Jay ; De Bats, Flore ; Montero, Javier ; Pesavento, Richard ; Misiuk-Hoilo, Marta ; Wykoff, Charles ; Narendran, Niro ; Mackiewicz, Jerzy ; Adan, Alfredo ; Varenhorst, Michael ; Flaxel, Christina ; Wang, Kun ; Hanscom, Thomas ; Katz, Randy ; Haegedorn, Curtis ; Studnicka, Jan ; Samuel, Michael ; Steinle, Nathan ; Khanani, Arshad ; Baumane, Kristine ; Ruiz Moreno, Jose Maria ; Menon, Geeta ; Jackson, Timothy ; Marcus, Denis ; Pieramici, Dante ; Baker, Carl ; Zarnowski, Tomasz ; Bandello, Francesco ; Randolf, John ; Boyer, David ; Mauget-Faysse, Martine ; Thach, Alan ; Staurenghi, Giovanni ; Garber, Frank ; Chang, Margaret ; Bridges, William ; Papp, Andras ; Hershberger, Vrinda ; Fernández-Vega, Alvaro ; Laganovska, Guna ; Thompson, John ; Gordon, Alan ; Facsko, Andrea ; Singer, Michael ; Goldstein, Michaella ; Baldwin, Megan E. ; Schneiderman, Todd ; Ciardella, Antonio ; Tsorbatzoglou, Alexis ; Stoller, Glenn ; Creuzot-Garcher, Catherine ; Kaiser, Peter ; Virgili, Gianni ; Buyse, Marc ; Jackson, Timothy L. ; Brooks, Harold ; Ohr, Matthew ; Pitcher, John ; Kerénvi, Agnes ; Brown, David ; Sivaprasad, Sobha ; Eichenbaum, David ; Shah, Sumit ; Chen, Sanford ; Strautmane, Ilze ; Kaluzny, Bartlomiej ; Patel, Sunil ; Ricci, Federico ; Wykoff, Charles C. ; Regillo, Carl ; Rubowitz, Alexander ; Crawford, Courtney

PURPOSENeovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C and D, which may explain why many patients fail to respond fully. This trial aimed to test the safety and efficacy of OPT-302, a biologic inhibitor of VEGF-C and D, in combination with the anti-VEGF-A inhibitor ranibizumab.DESIGNDose-ranging, phase 2b, randomized, double-masked, sham-controlled trial.PARTICIPANTSParticipants with treatment-naive nAMD were enrolled from 109 sites across Europe, Israel, and the United States.METHODSParticipants were randomized to 6, 4-weekly, intravitreal injections of 0.5 mg OPT-302, 2.0 mg OPT-302, or sham, plus intravitreal 0.5 mg ranibizumab.MAIN OUTCOME MEASURESThe primary outcome was mean change in ETDRS best-corrected visual acuity (BCVA) at 24 weeks. Secondary outcomes (comparing baseline with week 24) were the proportion of participants gaining or losing ≥ 15 ETDRS BCVA letters; area under the ETDRS BCVA over time curve; change in spectral-domain OCT (SD-OCT) central subfield thickness; and change in intraretinal fluid and subretinal fluid on SD-OCT.RESULTSOf 366 participants recruited from December 1, 2017, to November 30, 2018, 122, 123, and 121 were randomized to 0.5 mg OPT-302, 2.0 mg OPT-302, and sham, respectively. Mean (± standard deviation) visual acuity gain in the 2.0 mg OPT-302 group was significantly superior to sham (+14.2 ± 11.61 vs. +10.8 ± 11.52 letters; P = 0.01). The 0.5 mg OPT-302 group was not significantly different than the sham group (+9.44 ± 11.32 letters; P = 0.83). Compared with sham, the secondary BCVA outcomes favored the 2.0 mg OPT-302 group, with structural outcomes favoring both OPT-302 dosage groups. Adverse events (AEs) were similar across groups, with 16 (13.3%), 7 (5.6%), and 10 (8.3%) participants in the lower-dose, higher-dose, and sham groups, respectively, developing at least 1 serious AE. Two unrelated deaths both occurred in the sham arm.CONCLUSIONSSignificantly superior vision gain was observed with OPT-302 2.0 mg combination therapy, versus standard of care, with favorable safety (ClinicalTrials.gov identifier: NCT03345082).FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found after the references.

News (Medical) associated with Sozinibercept

16 Oct 2024

·www.globenewswire.com

Opthea Files Notice of Annual General Meeting

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the filing of the Notice of the Annual General Meeting and Explanatory Notes distributed to shareholders for the Company’s annual general meeting to be held virtually on Friday, 15 November 2024. Opthea’s current Executive Director, Dr. Megan Baldwin, PhD, MAICD, will retire from the Board at the conclusion of the annual general meeting in accordance with the ASX Listing Rules. Dr. Baldwin has decided not to seek re-election to the Board. As Founder and Chief Innovation Officer, Dr. Baldwin remains an integral and important part of the Company’s senior executive team as the Company approaches the anticipated sozinibercept wet AMD Phase 3 data readouts in 2025. “I look forward to focusing my efforts on leading Opthea’s innovation agenda in search of the next bold therapeutic approach in ophthalmology,” said Dr. Baldwin, Founder and Chief Innovation Officer, Opthea. “I am proud that sozinibercept could represent a breakthrough for millions of wet AMD patients to see better, a dream that I have nurtured over so many years.” “I want to express my sincere appreciation for the contributions Dr. Baldwin has made as a member of the Board of Directors,” concluded Jeremy Levin, D.Phil, MB BChir, Chairman of the Opthea Board of Directors. “Her leadership and insights have been very valuable helping to guide the Company through pivotal moments over the years. As the Company approaches an inflection point with the sozinibercept Phase 3 data readout, Dr. Baldwin will continue to advance Opthea’s broader innovation strategy.” Opthea is in the process of identifying a new director to fill the vacancy on the Board following Dr. Baldwin’s retirement from the Board. About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward Looking Statements This announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe”, “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this announcement include statements regarding the anticipated sozinibercept topline data timing for the two Phase 3 pivotal trials in wet AMD and Opthea’s innovation agenda. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept’s potential safety, tolerability and therapeutic efficacy, clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 30, 2024, as amended on September 20, 2024, and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, Pharm D, CEO Investor and Media Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pjkelleher@lifesciadvisors.com Phone: 617-430-7579 Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited

Phase 3Executive Change

30 Sep 2024

·www.globenewswire.com

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024. UBS Virtual Ophthalmology Day 2024 Fireside chat: Wednesday, October 2, 2024, 4:00 PM ETPresenter:Frederic Guerard, PharmD, CEOWebcast link:https://kvgo.com/ubs/opthea-ltd-oct-2024 The webcast can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com. About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited

Phase 3

23 Sep 2024

·www.globenewswire.com

Opthea Joins the S&P/ASX 300 Index

MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company joins the S&P/ASX 300 Index, effective Monday, September 23, 2024, prior to market open in Australia. “Opthea’s addition to the S&P/ASX 300 Index reflects the Company’s strengthened balance sheet with proceeds from the recent financing completed in July 2024. We also reached a significant milestone by completing enrollment of close to 2,000 patients in the sozinibercept Phase 3 wet AMD program,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “We believe our inclusion in the S&P/ASX 300 Index may further diversify the Company’s institutional shareholder base as we progress our Phase 3 pivotal program to anticipated topline data readouts of COAST in early Q2 calendar year 2025 and ShORe in mid calendar year 2025 and prepare the organization for a potential US FDA approval and launch.” The S&P/ASX indices measure the performance of ASX-listed companies across various sizes, industries, themes, and strategies. Each index is designed to represent a certain segment of the Australian equities market. The S&P/ASX 300 index, which is rebalanced semi-annually in March and September, measures the performance of 300 of Australia’s largest securities listed on the ASX by float-adjusted market capitalization. The index includes the large-cap, mid-cap, and small-cap components of the S&P/ASX index family. About Opthea Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-Looking Statements This ASX announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe,” “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding the potential for sozinibercept to treat highly prevalent and progressive retinal diseases, including wet AMD, the expected timing for top-line data for Opthea’s Phase 3 clinical trials of sozinibercept, the potential US FDA approval and launch of sozinibercept and the expectation that the inclusion of the Company in the S&P/ASX 300 Index may further diversify the Company’s institutional shareholder base. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept’s safety, tolerability and therapeutic efficacy, analysis of data from Opthea’s Phase 3 clinical trials, clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company, including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 30, 2024, and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, CEO. Investor Inquiries PJ KelleherLifeSci Advisors, LLCEmail: pkelleher@lifesciadvisors.com Phone: 617-430-7579 Media Inquiries Silvana Guerci-LenaNorthStream Global PartnersEmail: silvana@nsgpllc.com Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com Source: Opthea Limited

Phase 3

100 Deals associated with Sozinibercept

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet age-related macular degeneration	Phase 3	MY	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	BG	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	US	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	IL	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	DE	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	CZ	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	NL	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	PH	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	KR	Opthea Ltd.	12 Mar 2021
Wet age-related macular degeneration	Phase 3	PL	Opthea Ltd.	12 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03397264 (CTgov)	Phase 1/2	Diabetic macular oedema	153	aflibercept+OPT-302 (Ph 1b: 2.0 mg Aflibercept With 0.3 mg OPT-302)	tjlrhlopuh(zjipeuspma) = emhjzcirga clwvxlqhjc (zhqyzbwfzo, seeuykymxk - czrjzsoyzg) View more	-	22 Jun 2022
				aflibercept+OPT-302 (Ph 1b: 2.0 mg Aflibercept With 1.0 mg OPT-302)	tjlrhlopuh(zjipeuspma) = ppgaphpqjl clwvxlqhjc (zhqyzbwfzo, mibvaikwce - vdrbohlwpw) View more
NCT03345082 (ARVO2022)	Phase 2	Polypoidal choroidal vasculopathy	-	OPT-302 (0.5 mg) + Ranibizumab (0.5 mg)	(cpxdoavikr) = gnqpimfbub udmqnqiueb (ghacqovefs )	-	01 May 2022
				OPT-302 (2 mg) + Ranibizumab (0.5 mg)	(cpxdoavikr) = sckhuywjav udmqnqiueb (ghacqovefs )
NCT03397264 (GlobeNewswire) Manual	Phase 2	Diabetic macular oedema	115	Aflibercept+OPT-302	(albahhwwgg) = qkwxoqnfbu ssdzjtahuq (phnohsgojk ) View more	Positive	09 Jun 2020
				Aflibercept+Sham Procedure	(albahhwwgg) = jlnkboxqst ssdzjtahuq (phnohsgojk ) View more
NCT02543229 (Pubmed) Manual	Phase 1	Wet age-related macular degeneration	51	OPT-302	(rwqsueakqc) = wtfjgtwngq lhlbhcbhtg (rqbbrujwdh )	Positive	01 Mar 2020
				ranibizumab+OPT-302	(vusvoownlk) = ziqyjcotya igzinbftpi (wkrlqweyzx, 3 - 7) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis